A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Stopped Sponsor's decision to terminate the study after Stage 1; will not proceed with Stage 2.

Conditions

• Stomach Neoplasms
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Interventions

• DRUG: Atezolizumab
• DRUG: Tiragolumab
• DRUG: Oxaliplatin
• DRUG: Capecitabine

Sponsor

Hoffmann-La Roche